

*Stanley L. Mills, Ph.D.*  
***Mills Biopharmaceuticals Incorporated***

---

United States Nuclear Regulatory Commission  
Materials Safety Branch  
Division of Industrial and Medical Nuclear Safety  
Two White Flint North  
11545 Rockville Pike  
North Bethesda, MD 50852


13 June 1999

Dear Sir/Madam,

Attached is an **Application for Sealed Source and Device Evaluation and Registration**. I have enclosed one copy and a 3.5 inch disk in WordPerfect format of the Certificate which is included in the application. I hope this will assist you in your review and approval process. Please contact me by phone if you have any questions regarding this application.

Please consider this application for expedited review based upon the following considerations. There is a current shortage world wide for I-125 Brachytherapy seeds resulting in delays in treatment for a number of cancers. Current manufacturers are unable to supply the current demand. In addition, Mills Biopharmaceuticals is a small company and this application constitutes our first product. We have received the FDA 510(k) approval and a long delay in your evaluation process will place this company in a commercial hardship. I appreciate any consideration you can give regarding this request.

Sincerely,

  
Stanley L. Mills, Ph.D., R.Ph.  
President and CEO

---

120 N.E. 26th Street  
Oklahoma City, Oklahoma  
73105  
405-525-3141  
FAX 405-525-3143